SCHEMBL23905561

SCHEMBL23905561

CC(C)c1c(O[C@H]2C[C@H](C(=O)O)C2)nc2cc3[nH]ncc3cc2c1-c1ccc(F)cc1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.34
MKNK1 Q9BUB5 2/20 0.33
CTNNB1 P35222 1/20 0.33
WNT3A P56704 1/20 0.33
DGAT1 O75907 2/20 0.32
KCNH2 Q12809 1/20 0.32
ROCK2 O75116 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
NAMPT P43490 1/20 0.32
IDO1 P14902 1/20 0.31
GRIA1 P42261 1/20 0.31
ROCK1 Q13464 2/20 0.31
RPS6KB1 P23443 1/20 0.31
GRK2 P25098 1/20 0.31
GRK5 P34947 1/20 0.31
RPS6KA1 Q15418 1/20 0.31
SCN9A Q15858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23905564 1.00 MAPK1 (0.34) MAPK1MKNK1CTNNB1WNT3ADGAT1
SCHEMBL23884576 1.00 MAPK1 (0.34) MAPK1MKNK1CTNNB1WNT3ADGAT1
SCHEMBL30251784 1.00 MAPK1 (0.34) MAPK1MKNK1CTNNB1WNT3ADGAT1
SCHEMBL23905516 0.91 NPC1 (0.36) MAPK1DGAT1KCNH2ROCK2NPC1
SCHEMBL23905527 0.91 NPC1 (0.36) MAPK1DGAT1KCNH2ROCK2NPC1
SCHEMBL23884394 0.91 NPC1 (0.36) MAPK1DGAT1KCNH2ROCK2NPC1
SCHEMBL23884439 0.86 MAPK1 (0.38) MAPK1CTNNB1WNT3AROCK2NPC1
SCHEMBL30251803 0.86 MAPK1 (0.38) MAPK1CTNNB1WNT3AROCK2NPC1
SCHEMBL23884415 0.86 MKNK1 (0.36) MKNK1RPS6KB1
SCHEMBL30251849 0.86 MKNK1 (0.36) MKNK1RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
WO-2021203025-A1 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINE1, SERPINA3 MAPK1 1660/4885MKNK1 1481/4885CTNNB1 1365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.